World

AstraZeneca says its Coronavirus vaccine triggers immune response among adults

PHOTO CREDITS: FRANCE 24

According to CNBC, British pharmaceutical giant AstraZeneca on Monday said its potential COVID-19 vaccine has produced a similar Immune response in older and younger adults. 

AstraZeneca, in collaboration with Oxford University, said adverse responses to vaccines among the elderly were also found to be lower. The World Health Organization has said that older people, in addition to people of all ages with pre-existing medical conditions, appear to develop serious illness on contracting the Coronavirus more often than others.

“It is encouraging to see immunogenicity responses were similar between older and younger adults and that reactogenicity was lower in older adults, where the COVID-19 disease severity is higher,” an AstraZeneca spokesman told CNBC via email. “The results further build the body of evidence for the safety and immunogenicity of AZD1222,” the spokesman said, with reference to the technical name of the Oxford-AstraZeneca Vaccine. 

Side effects are common for new vaccines that are being developed for urgency. Johnson and Johnson, Pfizer and Modern, and many more universities and drugmakers’ vaccines showed side effects. Moreover, SARS-CoV-2 have spherical or pleomorphic enveloped particles containing single-stranded RNA associated with a nucleoprotein within a capsid composed of matrix protein or capsomere. This makes it more difficult to detect the virus’s deactivating location. All viruses can change their DNA or RNA structure, which makes it difficult for finding a new vaccine. 

Drugmakers and research centers are scrambling to deliver a safe and effective vaccine in an attempt to bring an end to the Coronavirus pandemic that had claimed over 1.18 million lives. Dozens of vaccines are in clinical evaluation, according to WHO, with some already conducting late-stage tests before seeking formal approval. The vaccine being developed by the University and AstraZeneca is thought to be one of the frontrunners to secure regulatory approval. AstraZeneca CEO Pascal Spirit lastly added, “AZD1222 would likely provide protection against contracting the Coronavirus for about a year.”

ARTICLE: PATEL CHAITANYA

SCIENCE/HEALTH EDITOR: KYLE SMITH

Leave a Reply